Literature DB >> 10758420

Genetic cholestasis: lessons from the molecular physiology of bile formation.

P L Jansen1, M Müller.   

Abstract

Progressive familial intrahepatic cholestasis (PFIC) is a group of severe genetic cholestatic liver diseases of early life. PFIC types 1 and 2 are characterized by cholestasis and a low to normal serum gamma-glutamyltransferase (GGT) activity, whereas in PFIC type 3, the serum GGT activity is elevated. PFIC types 1 and 2 occur due to mutations in loci at chromosome 18 and chromosome 2, respectively. The pathophysiology of PFIC type 1 is not well understood. PFIC types 2 and 3 are caused by transport defects in the liver affecting the hepatobiliary secretion of bile acids and phospholipids, respectively. Benign recurrent intrahepatic cholestasis (BRIC) is linked to a mutation in the same familial intrahepatic cholestasis 1 locus at chromosome 18. Defects of bile acid synthesis may be difficult to differentiate from these transport defects. Intrahepatic cholestasis of pregnancy (ICP) appears to be related to these cholestatic diseases. For example, heterozygosity in families with PFIC type 3 is associated with ICP, but ICP has also been reported in families with BRIC. In Dubin-Johnson syndrome there is no cholestasis; only the hepatobiliary transport of conjugated bilirubin is affected. This, therefore, is a mild disease, and patients have a normal lifespan.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10758420     DOI: 10.1155/2000/514172

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  5 in total

1.  A missense mutation (R565W) in cirhin (FLJ14728) in North American Indian childhood cirrhosis.

Authors:  Pierre Chagnon; Jacques Michaud; Grant Mitchell; Jocelyne Mercier; Jean-François Marion; Eric Drouin; Andrée Rasquin-Weber; Thomas J Hudson; Andrea Richter
Journal:  Am J Hum Genet       Date:  2002-11-04       Impact factor: 11.025

Review 2.  A perspective on efflux transport proteins in the liver.

Authors:  K Köck; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2012-09-05       Impact factor: 6.875

3.  Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI.

Authors:  Rosa Chan; Leslie Z Benet
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

Review 4.  Progressive familial intrahepatic cholestasis.

Authors:  Anshu Srivastava
Journal:  J Clin Exp Hepatol       Date:  2013-11-23

5.  Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4.

Authors:  Kathleen Köck; Brian C Ferslew; Ida Netterberg; Kyunghee Yang; Thomas J Urban; Peter W Swaan; Paul W Stewart; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2013-10-23       Impact factor: 3.922

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.